Currently, there are ongoing phases II and phase III clinical trials attempting to clarify the role of HIPEC for the treatment of EOC. Literature suggests that in appropriately selected patient populations, HIPEC may confer both a PFS and OS benefit. Our data supports a reasonable side effect profile of several HIPEC regimens for patients with EOC for multiple treatment indications. Future studies designed to determine which cytotoxic agents would provide the most benefit in patients with EOC are needed.


Michelle M. Boisen1, Scott D. Richard2, Matthew P. Holtzman3, Robert P. Edwards1, Joseph L. Kelley1, Mohammad Haroon Choudry3, David Bartlett3, Marilyn Huang1


Continue Reading

1Division of Gynecologic Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA; 2Division of Gynecologic Oncology, Hahnemann University Hospital, Philadelphia, PA, USA; 3Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA 


Contributions: (I) Conception and design: MM Boisen, M Huang; (II) Administrative support: M Huang, MH Choudry; (III) Provision of study materials or patients: SD Richard, MP Holtzman, MH Choudry, D Bartlett, RP Edwards, M Huang; (IV) Collection and assembly of data: MM Boisen, M Huang, SD Richard, MP Holtzman, MH Chourdry; (V) Data analysis and interpretation: MM Boisen, M Huang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Michelle M. Boisen, MD. Magee-Womens Hospital of UPMC, 300 Halket St., Suite 2130, Pittsburgh, PA 15213, USA. Email: [email protected].  


Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. [PubMed]

2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29. [PubMed]

3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200. [PubMed]

4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. [PubMed]

5. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59. [PubMed]

6. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53. [PubMed]

7. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6. [PubMed]

8. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-8. [PubMed]

9. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50. [PubMed]

10. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. [PubMed]